Exicure Inc is expected to report a Q3 2026 revenue consensus of $1.64 million and an EPS loss of $18.60, with shares currently trading near $1.02 relative to an uncertain analyst price target. Investors are primarily focused on the company’s ability to regain Nasdaq compliance by meeting the $2.5 million stockholders’ equity requirement before the December 2, 2026, deadline.
This report follows a strategic shift toward the development of Burixafor (GPC-100) under a co-development agreement with Adbiotech. However, management’s recent "going concern" warning has heightened market anxiety regarding the company’s current cash runway and overall liquidity position.